{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:46:57Z","timestamp":1791726417334,"version":"4.3.4"},"reference-count":113,"publisher":"SAABRON PRESS","issue":"4","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Chronic graft-versus-host disease (cGVHD) represents a common long-term complication after allogeneic hematopoietic stem cell transplantation (HSCT). It imposes a significant morbidity burden and is the leading cause of non-relapse mortality among long-term HSCT survivors. cGVHD can manifest in nearly any organ, severely affecting the quality of life of a transplant survivor. While the mainstay of treatment has remained systemic immunosuppression with glucocorticoids, progress has been made within the last few years with approvals of three oral agents to treat steroid-refractory cGVHD: ibrutinib, ruxolitinib, and belumosudil. Iatrogenesis contributes a significant portion of the morbidity experienced by patients with cGVHD, primarily from glucocorticoids. This review highlights the myriad impacts of cGVHD, including and beyond the traditional organ systems captured by the National Institutes of Health Consensus Criteria, including iatrogenic complications of long-term immunosuppression. It presents the implications of cGVHD and its treatment on cardiovascular and metabolic health, bone density, endocrine function, sexual health, and ocular and pulmonary disease and outlines a framework around the comprehensive multidisciplinary approach for its evaluation and management.<\/jats:p>","DOI":"10.46989\/001c.124926","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T14:36:38Z","timestamp":1729521398000},"source":"Crossref","is-referenced-by-count":24,"title":["Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease"],"prefix":"10.46989","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-4690","authenticated-orcid":true,"given":"Rahul","family":"Shah","sequence":"first","affiliation":[{"name":"Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center"},{"name":"Department of Medicine, Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Murphy","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Logue","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Jerkins","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jallouk","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassim","family":"Adetola","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan","family":"Oluwole","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Jayani","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eden","family":"Biltibo","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae K.","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salyka","family":"Sengsayadeth","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichai","family":"Chinratanalab","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Kitko","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Pediatrics, Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Savani","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"issue":"5","key":"ref1","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1016\/j.bbmt.2018.11.033","article-title":"Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"Y. Inamoto","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"6","key":"ref2","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00417-015-2940-3","article-title":"Outcomes of phacoemulsification in patients with chronic ocular graft-versus-host disease","volume":"253","author":"U. S. Saboo","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"ref3","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00417-016-3312-3","article-title":"Prevalence of ocular hypertension and glaucoma in patients with chronic ocular graft-versus-host disease","volume":"254","author":"U. S. Saboo","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"ref4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1182\/blood-2016-08-693507","article-title":"How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation","volume":"129","author":"K. M. Williams","year":"2017","journal-title":"Blood"},{"issue":"7","key":"ref5","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.bbmt.2010.11.018","article-title":"Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation","volume":"17","author":"B.K.C. Au","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"ref6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jtct.2022.11.012","article-title":"Noninfectious Pulmonary Complications after Hematopoietic Stem Cell Transplantation","volume":"29","author":"J. Fraebel","year":"2023","journal-title":"Transplantation and Cellular Therapy"},{"issue":"4","key":"ref7","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.bbmt.2015.10.009","article-title":"Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation","volume":"22","author":"K. M. Williams","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"ref8","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1111\/j.1600-6143.2010.03187.x","article-title":"Solid Organ Transplantation After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective, Multicenter Study of the EBMT","volume":"10","author":"C. Koenecke","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"11","key":"ref9","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/j.bbmt.2020.08.002","article-title":"Driving Distance and Patient-Reported Outcomes in Hematopoietic Cell Transplantation Survivors","volume":"26","author":"R. Banerjee","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"ref10","doi-asserted-by":"publisher","first-page":"131.e1","DOI":"10.1016\/j.jtct.2022.10.028","article-title":"Primary Preventive Care of Hematopoietic Stem Cell Transplantation Survivors: Time to Educate and Empower Recipients and Providers","volume":"29","author":"J. Fulcher","year":"2023","journal-title":"Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy"},{"issue":"1","key":"ref11","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/hematology.2019000004","article-title":"Cause-specific late mortality after allogeneic stem cell transplantation","volume":"2019","author":"S. Bhatia","year":"2019","journal-title":"Hematology"},{"issue":"1","key":"ref12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1182\/asheducation-2014.1.495","article-title":"Caring for the long-term survivor after allogeneic stem cell transplantation","volume":"2014","author":"S. Bhatia","year":"2014","journal-title":"Hematology"},{"issue":"1","key":"ref13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/bmt.2015.210","article-title":"Next generation long term transplant clinics: Improving resource utilization and the quality of care through health information technology","volume":"51","author":"M. J. Rioth","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"ref14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/CCO.0000000000000996","article-title":"Machine learning applications and challenges in graft-versus-host disease: a scoping review","volume":"35","author":"A. H. Mushtaq","year":"2023","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"ref15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43856-023-00299-5","article-title":"A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"3","author":"T. Jo","year":"2023","journal-title":"Commun Med"},{"issue":"9","key":"ref16","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-14-0586","article-title":"Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia","volume":"21","author":"M. Boyiadzis","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"20","key":"ref17","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium","volume":"5","author":"Z. DeFilipp","year":"2021","journal-title":"Blood Advances"},{"issue":"10","key":"ref18","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.bbmt.2017.06.011","article-title":"Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease","volume":"23","author":"S. Kurosawa","year":"2017","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"9","key":"ref19","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3324\/haematol.2018.192930","article-title":"Patient-reported outcomes and health status associated with chronic graft-versus-host disease","volume":"103","author":"S. J. Lee","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"ref20","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report","volume":"11","author":"A. H. Filipovich","year":"2005","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"4","key":"ref21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","article-title":"How we treat chronic graft-versus-host disease","volume":"125","author":"M. E. D. Flowers","year":"2015","journal-title":"Blood"},{"issue":"4","key":"ref22","first-page":"351","article-title":"Ocular graft versus host disease following allogeneic stem cell transplantation: a review of current knowledge and recommendations","volume":"8","author":"N. Nassiri","year":"2013","journal-title":"J Ophthalmic Vis Res"},{"issue":"4","key":"ref23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.det.2019.05.014","article-title":"Review of Graft-Versus-Host Disease","volume":"37","author":"V. Ramachandran","year":"2019","journal-title":"Dermatol Clin"},{"issue":"17","key":"ref24","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1182\/blood-2012-05-393389","article-title":"How we treat oral chronic graft-versus-host disease","volume":"120","author":"N. Treister","year":"2012","journal-title":"Blood"},{"issue":"1","key":"ref25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1182\/asheducation-2008.1.134","article-title":"Recognizing and Managing Chronic Graft-Versus-Host Disease","volume":"2008","author":"S. J. Lee","year":"2008","journal-title":"Hematology"},{"issue":"1","key":"ref26","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1182\/hematology.2021000302","article-title":"What else do I need to worry about when treating graft-versus-host disease?","volume":"2021","author":"A. El-Jawahri","year":"2021","journal-title":"Hematology"},{"issue":"10","key":"ref27","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1200\/JCO.22.00509","article-title":"Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study","volume":"41","author":"D. B. Miklos","year":"2023","journal-title":"JCO"},{"issue":"21","key":"ref28","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1182\/blood-2009-02-202937","article-title":"Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease","volume":"113","author":"P. J. Martin","year":"2009","journal-title":"Blood"},{"issue":"2","key":"ref29","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1182\/blood.V72.2.546.546","article-title":"Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation","volume":"72","author":"K. M. Sullivan","year":"1988","journal-title":"Blood"},{"issue":"11","key":"ref30","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41409-019-0544-y","article-title":"Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"54","author":"L. Axt","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"ref31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease","volume":"385","author":"R. Zeiser","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"ref32","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/oncolo\/oyac076","article-title":"Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease","volume":"27","author":"D. J. Martini","year":"2022","journal-title":"The Oncologist"},{"issue":"21","key":"ref33","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"D. Miklos","year":"2017","journal-title":"Blood"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02256","article-title":"Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease","author":"R. Zeiser","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"ref35","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1182\/asheducation-2017.1.639","article-title":"Extracorporeal photopheresis: cellular therapy for the treatment of acute and chronic graft-versus-host disease","volume":"2017","author":"J. Schneiderman","year":"2017","journal-title":"Hematology"},{"issue":"3","key":"ref36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"M. H. Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"ref37","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jtct.2023.07.001","article-title":"Extracorporeal Photopheresis in Graft-versus-Host Disease","volume":"29","author":"P. A. Cant\u00f3","year":"2023","journal-title":"Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy"},{"issue":"5","key":"ref38","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41409-018-0333-z","article-title":"Challenges in managing graft-versus-host disease in developing countries: a perspective","volume":"54","author":"M. S. Saleem","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"ref39","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1182\/blood-2012-05-426783","article-title":"Economics of hematopoietic cell transplantation","volume":"120","author":"N. Khera","year":"2012","journal-title":"Blood"},{"issue":"9","key":"ref40","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1038\/s41409-021-01389-5","article-title":"Steroid-refractory chronic graft-versus-host disease: treatment options and patient management","volume":"56","author":"D. Wolff","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"09636897221113789","DOI":"10.1177\/09636897221113789","article-title":"Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD","volume":"31","author":"D. W. Baek","year":"2022","journal-title":"Cell Transplant"},{"issue":"3","key":"ref42","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1182\/blood-2014-01-514752","article-title":"Current issues in chronic graft-versus-host disease","volume":"124","author":"G. Soci\u00e9","year":"2014","journal-title":"Blood"},{"issue":"11","key":"ref43","doi-asserted-by":"publisher","first-page":"E348","DOI":"10.1002\/ajh.25236","article-title":"Antibiotic practice patterns in hematopoietic cell transplantation: A survey of Blood and Marrow Transplant Clinical Trials Network centers","volume":"93","author":"A. Rashidi","year":"2018","journal-title":"Am J Hematol"},{"issue":"19","key":"ref44","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood.2019000960","article-title":"How I treat steroid-refractory acute graft-versus-host disease","volume":"135","author":"P. J. Martin","year":"2020","journal-title":"Blood"},{"issue":"6","key":"ref45","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/s41409-022-01680-z","article-title":"Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia","volume":"57","author":"A. Ohmoto","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"ref46","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3324\/haematol.12949","article-title":"Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation","volume":"93","author":"A. Tichelli","year":"2008","journal-title":"Haematologica"},{"issue":"26","key":"ref47","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets","volume":"377","author":"R. Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"ref48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12944-022-01665-3","article-title":"Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation","volume":"21","author":"Y. Lu","year":"2022","journal-title":"Lipids in Health and Disease"},{"issue":"4","key":"ref49","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jaccao.2023.03.013","article-title":"Prediction of Coronary Heart Disease Events in Blood or Marrow Transplantation Recipients","volume":"5","author":"R. Gangaraju","year":"2023","journal-title":"JACC: CardioOncology"},{"issue":"11","key":"ref50","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1038\/s41409-021-01414-7","article-title":"Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study","volume":"56","author":"D. M. Greenfield","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and Management of the Metabolic Syndrome","author":"S. M. Grundy","year":"2005","journal-title":"Circulation"},{"issue":"10","key":"ref52","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1161\/01.CIR.0000140677.20606.0E","article-title":"Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults","volume":"110","author":"S. Malik","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"ref53","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/bmt.2008.263","article-title":"High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation","volume":"43","author":"N. S. Majhail","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"ref54","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.bbmt.2009.05.010","article-title":"Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation","volume":"15","author":"N. S. Majhail","year":"2009","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"4","key":"ref55","doi-asserted-by":"publisher","first-page":"699","DOI":"10.4158\/EP10027.RA","article-title":"Diabetes Mellitus after Hematopoietic Stem Cell Transplantation","volume":"16","author":"M. L. Griffith","year":"2010","journal-title":"Endocrine Practice"},{"issue":"12","key":"ref56","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41409-023-02097-y","article-title":"Metabolic syndrome prevalence and impact on outcomes in patients with chronic graft-versus-host disease","volume":"58","author":"A.T. Zhao","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"ref57","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.21873\/invivo.12197","article-title":"New-onset Post-transplant Diabetes and Therapy in Long-term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"34","author":"V. Dalla Via","year":"2020","journal-title":"In Vivo"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"4","DOI":"10.12703\/r\/12-4","article-title":"Recent advances in graft-versus-host disease","volume":"12","author":"A.M. Flinn","year":"2023","journal-title":"Fac Rev"},{"issue":"6","key":"ref59","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.bbmt.2019.02.001","article-title":"New-Onset Post-Transplant Diabetes Mellitus after Allogeneic Hematopoietic Cell Transplant Is Initiated by Insulin Resistance, Not Immunosuppressive Medications","volume":"25","author":"B. G. Engelhardt","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"ref60","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.bbmt.2008.11.032","article-title":"Prolonged chronic GVHD is a risk factor for thyroid failure in long-term survivors after matched sibling donor stem cell transplantation for hematological malignancies","volume":"15","author":"B. N. Savani","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"ref61","doi-asserted-by":"publisher","first-page":"485","DOI":"10.4158\/EP-2018-0529","article-title":"ENDOCRINE COMPLICATIONS IN PATIENTS WITH GVHD","volume":"25","author":"A. Akirov","year":"2019","journal-title":"Endocr Pract"},{"issue":"25","key":"ref62","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1161\/CIRCULATIONAHA.118.036859","article-title":"Thyroid and Cardiovascular Disease","volume":"139","author":"A. R. Cappola","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"ref63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1741-7015-12-47","article-title":"Is atherosclerosis an autoimmune disease?","volume":"12","author":"E. Matsuura","year":"2014","journal-title":"BMC Medicine"},{"issue":"4","key":"ref64","doi-asserted-by":"publisher","first-page":"180","DOI":"10.2991\/chi.d.190917.001","article-title":"Managing Endocrine Disorders in Adults After Hematopoietic Stem Cell Transplantation","volume":"1","author":"J. Matthews","year":"2019","journal-title":"Clin Hematol Int"},{"issue":"11","key":"ref65","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1016\/j.bbmt.2020.08.004","article-title":"Challenging and Practical Aspects of Nutrition in Chronic Graft-versus-Host Disease","volume":"26","author":"A. Z. Pereira","year":"2020","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"1","key":"ref66","doi-asserted-by":"publisher","first-page":"e0293873","DOI":"10.1371\/journal.pone.0293873","article-title":"The effect of oral chronic graft-versus-host disease on bodyweight: A cohort study","volume":"19","author":"A. A. Aboalela","year":"2024","journal-title":"PLoS One"},{"issue":"11","key":"ref67","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1007\/s00432-020-03280-0","article-title":"Sarcopenia among patients after allogeneic hematopoietic stem cell transplantation and the impact of chronic graft-versus-host disease","volume":"146","author":"D. Ljubas Kelecic","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"ref68","doi-asserted-by":"publisher","first-page":"7111","DOI":"10.1007\/s00520-021-06334-2","article-title":"The effect of exercise and nutrition interventions on physical functioning in patients undergoing haematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"29","author":"M. C. Prins","year":"2021","journal-title":"Support Care Cancer"},{"issue":"11","key":"ref69","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"M. E. D. Flowers","year":"2011","journal-title":"Blood"},{"issue":"1","key":"ref70","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/bmt.2017.155","article-title":"Is there any role for physical therapy in chronic GvHD?","volume":"53","author":"J. Mohammed","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"ref71","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s12885-022-09497-1","article-title":"Impact of Resistance Exercise and Nutritional Endorsement on physical performance in patients with GvHD (IRENE-G study) \u2013 design and rational of a randomized controlled trial","volume":"22","author":"J. Bujan Rivera","year":"2022","journal-title":"BMC Cancer"},{"issue":"10","key":"ref72","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1182\/blood-2004-09-3411","article-title":"Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study","volume":"105","author":"R. E. Curtis","year":"2005","journal-title":"Blood"},{"issue":"11","key":"ref73","doi-asserted-by":"publisher","first-page":"937.e1","DOI":"10.1016\/j.jtct.2021.08.001","article-title":"Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease","volume":"27","author":"D. A. Schaar","year":"2021","journal-title":"Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy"},{"issue":"7","key":"ref74","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.bbmt.2010.10.032","article-title":"Cigarette Smoking and Outcomes After Allogeneic Hematopoietic Stem Cell Transplant","volume":"17","author":"B. T. Tran","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"ref75","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.bbmt.2009.06.005","article-title":"THE EFFECT OF SMOKING ON ALLOGENEIC TRANSPLANT OUTCOMES","volume":"15","author":"D. I. Marks","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"ref76","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/cncr.31227","article-title":"Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation","volume":"124","author":"K. J. Leger","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"ref77","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jtct.2023.12.001","article-title":"International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update","volume":"30","author":"S. J. Rotz","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"ref78","doi-asserted-by":"publisher","first-page":"624","DOI":"10.2188\/jea.JE20220175","article-title":"Cancer Risk According to Alcohol Consumption Trajectories: A Population-based Cohort Study of 2.8 Million Korean Men","volume":"33","author":"T. T. Bui","year":"2023","journal-title":"J Epidemiol"},{"issue":"8","key":"ref79","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.bbmt.2016.04.012","article-title":"Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host Disease","volume":"22","author":"F. Pirsl","year":"2016","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"8","key":"ref80","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/sj.bmt.1701423","article-title":"Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis","volume":"22","author":"S. Carlens","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"100361","DOI":"10.1016\/j.jbo.2021.100361","article-title":"Osteoporosis management in hematologic stem cell transplant recipients: Executive summary","volume":"28","author":"D. L. Kendler","year":"2021","journal-title":"J Bone Oncol"},{"issue":"7","key":"ref82","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/humrep\/deg295","article-title":"Gonadal status in reproductive age women after haematopoietic stem cell transplantation for haematological malignancies","volume":"18","author":"L. Tauchmanov\u00e0","year":"2003","journal-title":"Human Reproduction"},{"issue":"5","key":"ref83","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1210\/jc.2009-0205","article-title":"Approach to the Patient with Transplantation-Related Bone Loss","volume":"94","author":"P. R. Ebeling","year":"2009","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"3","key":"ref84","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1359\/jbmr.1999.14.3.342","article-title":"Mechanisms of Bone Loss Following Allogeneic and Autologous Hemopoietic Stem Cell Transplantation","volume":"14","author":"P. R. Ebeling","year":"1999","journal-title":"Journal of Bone and Mineral Research"},{"issue":"3","key":"ref85","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.bbmt.2011.12.519","article-title":"Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation","volume":"18","author":"N. S. Majhail","year":"2012","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"10","key":"ref86","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician\u2019s guide to prevention and treatment of osteoporosis","volume":"33","author":"M. S. LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"issue":"1","key":"ref87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bmt.2010.198","article-title":"Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients","volume":"46","author":"B. L. McClune","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"ref88","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management","volume":"84","author":"K. A. Kennel","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"ref89","series-title":"StatPearls","article-title":"Bisphosphonate Related Jaw Osteonecrosis","author":"M. Gupta","year":"2024"},{"issue":"9","key":"ref90","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.bbmt.2010.03.008","article-title":"Corticosteroid Dose as a Risk Factor for Avascular Necrosis of the Bone after Hematopoietic Cell Transplantation","volume":"16","author":"S. McAvoy","year":"2010","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"24","key":"ref91","doi-asserted-by":"publisher","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","article-title":"How much has allogeneic stem cell transplant\u2013related mortality improved since the 1980s? A retrospective analysis from the EBMT","volume":"4","author":"O. Penack","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"ref92","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1182\/blood-2002-07-2231","article-title":"Nonmalignant late effects after allogeneic stem cell transplantation","volume":"101","author":"G. Soci\u00e9","year":"2003","journal-title":"Blood"},{"issue":"10","key":"ref93","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/cncr.11373","article-title":"Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation","volume":"97","author":"L. Tauchmanov\u00e0","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"ref94","doi-asserted-by":"publisher","first-page":"101243","DOI":"10.1016\/j.beha.2021.101243","article-title":"How old is too old for a transplant?","volume":"34","author":"D. Weisdorf","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"ref95","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1053\/j.seminhematol.2011.10.002","article-title":"Female long term survivors after allo-HSCT: evaluation and management","volume":"49","author":"D. Shanis","year":"2012","journal-title":"Semin Hematol"},{"issue":"24","key":"ref96","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1001\/jama.2019.19191","article-title":"Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease","volume":"322","author":"M. C. Honigberg","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"ref97","doi-asserted-by":"publisher","first-page":"335.e1","DOI":"10.1016\/j.jtct.2021.10.013","article-title":"Male-specific late effects in adult hematopoietic cell transplantation recipients","volume":"28","author":"R. Phelan","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"ref98","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3324\/haematol.2012.071944","article-title":"Ongoing graft-versus-host disease is a risk factor for azoospermia after allogeneic hematopoietic stem cell transplantation: a survey of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation","volume":"98","author":"A. Rov\u00f3","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"ref99","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/bjh.13872","article-title":"A survey of fertility and sexual health following allogeneic haematopoietic stem cell transplantation in New South Wales, Australia","volume":"172","author":"G. Dyer","year":"2016","journal-title":"Br J Haematol"},{"issue":"24","key":"ref100","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1182\/blood-2013-05-499806","article-title":"Longitudinal trajectory of sexual functioning after hematopoietic cell transplantation: impact of chronic graft-versus-host disease and total body irradiation","volume":"122","author":"F. L. Wong","year":"2013","journal-title":"Blood"},{"issue":"5","key":"ref101","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.3390\/jcm11051196","article-title":"Sexual and Emotional Health after Allogeneic Hematopoietic Cell Transplantation: A Comprehensive Review and Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"11","author":"T. Alsuliman","year":"2022","journal-title":"J Clin Med"},{"issue":"11","key":"ref102","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1001\/jamaoncol.2021.3676","article-title":"Trends in Late Mortality and Life Expectancy After Allogeneic Blood or Marrow Transplantation Over 4 Decades: A Blood or Marrow Transplant Survivor Study Report","volume":"7","author":"S. Bhatia","year":"2021","journal-title":"JAMA Oncology"},{"issue":"23","key":"ref103","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1002\/cncr.29675","article-title":"Sexual Health in Hematopoietic Stem Cell Transplant Recipients","volume":"121","author":"Z. Li","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"ref104","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.htct.2018.06.005","article-title":"Female genital tract chronic graft-versus-host disease: A narrative review","volume":"41","author":"A. M. N. Machado","year":"2019","journal-title":"Hematol Transfus Cell Ther"},{"issue":"6","key":"ref105","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/bmt.2016.315","article-title":"Clinical management of genital chronic GvHD","volume":"52","author":"B.K. Hamilton","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"ref106","article-title":"Hormone Therapy in Primary Ovarian Insufficiency","journal-title":"American College of Obstetricians and Gynecologists"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"564781","DOI":"10.3389\/fendo.2021.564781","article-title":"Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts","volume":"12","author":"J. Mehta","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"ref108","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.bbmt.2013.07.010","article-title":"Genital Chronic GVHD in Men after Hematopoietic Stem Cell Transplantation: A Single-Center Cross-Sectional Analysis of 155 Patients","volume":"19","author":"S. M. Mueller","year":"2013","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"3","key":"ref109","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/1024533021000008182","article-title":"Peyronie\u2019s disease as a complication of chronic graft versus host disease","volume":"7","author":"A. P. Grigg","year":"2002","journal-title":"Hematology"},{"key":"ref110","series-title":"Blood and Marrow Transplantation Long Term Management","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/9781119612780.ch23","article-title":"Sexual Dysfunction in Long-Term Survivors","author":"R. L. Hunter","year":"2021"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"1092108","DOI":"10.3389\/fimmu.2023.1092108","article-title":"Recent advances in ocular graft-versus-host disease","volume":"14","author":"X. Cheng","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"ref112","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/ICO.0000000000002526","article-title":"Prevalence and Risk Factors Associated With Corneal Perforation in Chronic Ocular Graft-Versus-Host-Disease","volume":"40","author":"S. Sinha","year":"2021","journal-title":"Cornea"},{"issue":"2","key":"ref113","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"S. Arai","year":"2015","journal-title":"Biology of Blood and Marrow Transplantation"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/124926-multidisciplinary-management-of-morbidities-associated-with-chronic-graft-versus-host-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:26:09Z","timestamp":1791725169000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/124926-multidisciplinary-management-of-morbidities-associated-with-chronic-graft-versus-host-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":113,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.124926","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]}}}